Patent application number | Description | Published |
20150148859 | ACTIVE IMPLANTABLE MEDICAL DEVICE FOR ATRIAL STIMULATION FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION - An active implantable medical device includes digital processor circuits configured to sense right and left atrial depolarizations and deliver left atrial stimulation pulses according to a stimulation protocol. The stimulation protocol includes delivering a left atrial stimulation pulse at an inter-atrial coupling interval. The inter-atrial coupling interval is a coupling interval shorter than the sinus rhythm coupling interval, so as to deliver a premature pulse. The protocol further includes delivering a not premature left-atrial stimulation pulse during an immediately subsequent cardiac cycle, at an inter-atrial coupling interval corresponding to the sinus rhythm coupling interval. The protocol also includes assessing the right atrial coupling interval between the right atrial depolarizations and comparing the right atrial coupling interval to the sinus rhythm coupling interval. And finally, modifying an adjustable controlling parameters if necessary according to the result of the comparison. The device has no means for collecting and analyzing the endocardial acceleration. | 05-28-2015 |
20150196770 | NEURAL NETWORK SYSTEM FOR THE EVALUATION AND THE ADAPTATION OF ANTITACHYCARDIA THERAPY BY AN IMPLANTABLE DEFIBRILLATOR - The system includes an active medical device with means for delivering defibrillation shocks; means for continuous collection of the patient current cardiac activity parameters; and evaluator means with neuronal analysis comprising a neural network with at least two layers. This neural network comprises upstream three neural sub-networks receiving the respective parameters divided into separate sub-groups corresponding to classes of arrhythmogenic factors; and downstream an output neuron coupled to the three sub-networks and capable of outputting an index of risk of ventricular arrhythmia. The risk index is compared with a given threshold, to enable or disable at least one function of the device in case of crossing of the threshold. | 07-16-2015 |
20150224017 | DEVICE FOR DISCRIMINATION OF STAGES OF A PATIENT'S SLEEP - A device for treating sleep apnea by discriminating between successive sleep stages of a patient includes a generator configured to produce stimulation pulses, a stimulator that receives the stimulation pulses produced by the generator and delivers stimulation to the patient, a sensor configured to measure a biological parameter of the patient, and a controller. The controller is configured to determine a state of the patient based on the biological parameter, perform a sleep analysis based on the state of the patient, activate the generator to trigger production of the stimulation pulses, determine a variation of the biological parameter subsequent to the production of the stimulation pulses, determine a response of the patient to the stimulation pulses according to the variation of the biological parameter, and determine a sleep stage of the patient based on the response. | 08-13-2015 |
20150224018 | DEVICE FOR THE TREATMENT OF SLEEP APNEA SYNDROME IN A PATIENT BY KINESTHETIC STIMULATION - A device for treating sleep apnea in a patient through stimulation. The device includes a generator configured to produce stimulation pulses, a stimulator that receives the stimulation pulses produced by the generator and delivers stimulation to the patient, and a controller. The controller is configured to determine a sleep state of the patient, adaptively control the generator based on the sleep state where the sleep state includes a plurality of sleep stages, and modulate a stimulation energy of the stimulation pulses produced by the generator based on the sleep stage of the patient | 08-13-2015 |
Patent application number | Description | Published |
20120022607 | VENTRICULAR CAPTURE TESTING BY ANALYSIS OF AN ENDOCARDIAL ACCELERATION SIGNAL IN AN ACTIVE IMPLANTABLE MEDICAL DEVICE - An active implantable medical device such as a cardiac prosthesis, including ventricular capture testing by analysis of an endocardial acceleration signal. The device isolates in an endocardial acceleration (“EA”) signal an EA component, extracts from it, n representative indicators (PEA_i, LEA_i), and forms a vector EA (X_i) from these indicators. A classifier allows acquiring reference EA signals at a stimulation energy level sufficient to cause a capture, and in spontaneous rhythm in the absence of ventricular pacing and forms a corresponding plurality of first reference EA vectors. The n-dimensional space of the EA vectors is partitioned into two corresponding subspaces. The presence or absence of a capture is discriminated based on the position of the current EA vector (X_i) in one or other of these two sub-spaces. The representative indicators may be: the value of peak to peak amplitude, the width, the moment of occurrence of the peak, the starting time and the ending time of the EA | 01-26-2012 |
20130304144 | VENTRICULAR CAPTURE TESTING BY ANALYSIS OF AN ENDOCARDIAL ACCELERATION SIGNAL IN AN ACTIVE IMPLANTABLE MEDICAL DEVICE - A processor-based method for use with an active implantable medical device for cardiac pacing, resynchronization, and/or defibrillation includes forming a plurality of first and second endocardial acceleration vectors using a plurality of endocardial acceleration signals acquired using stimulation to cause capture and a spontaneous rhythm of the patient in the absence of ventricular pacing, respectively. An at least two dimension space is created using the first and second endocardial acceleration vectors, including two subspaces corresponding to the presence and absence of capture, respectively. Ventricular capture is tested for after acquiring a new endocardial acceleration signal. The testing includes forming a new endocardial acceleration signal based on the new vector. Presence or absence of capture is determined for the new signal based on the position of the new vector relative to the two subspaces. | 11-14-2013 |
Patent application number | Description | Published |
20130210774 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS - The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection. | 08-15-2013 |
20140235566 | PYRIMIDINE NUCLEOSIDES AND THEIR MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS AND CANCER - The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, or HBV in human patients or other animal hosts. The compounds are certain N | 08-21-2014 |
20140350016 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS - The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection. | 11-27-2014 |
Patent application number | Description | Published |
20080300298 | Honokiol Derivates For the Treatment of Proliferative Disorders - The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of cancer. In particular, honokiol derivatives, pharmaceutical compositions comprising the derivatives, and methods for their use in the treatment of myeloma are provided. | 12-04-2008 |
20100279969 | AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3′-azido-2′,3′-dideoxy purine nucleosides or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 resistance mutants including HIV-1 | 11-04-2010 |